PLK1

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Retrieved on: 
Jeudi, mai 2, 2024
Clinical Cancer Research, SCLC, CRDF, RAS, Trial of the century, Carcinoma, Patient, AACR, Cancer, Bev, PLK1, Ovarian cancer, SAN, Pharmaceutical industry

Company highlights for the quarter ended March 31, 2024 and subsequent weeks include:

Key Points: 
  • Company highlights for the quarter ended March 31, 2024 and subsequent weeks include:
    Presented updated data at AACR Annual Meeting 2024 that supports ongoing first-line RAS-mutated mCRC clinical study.
  • Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • As of March 31, 2024, Cardiff Oncology had approximately $67.2 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Retrieved on: 
Jeudi, avril 25, 2024
CRDF, Cancer, PLK1, SAN

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.

Key Points: 
  • - Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT -
    SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.
  • Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024.
  • Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events .
  • A replay will be available in the investor relations section on the company's website following the completion of the call.

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

Retrieved on: 
Mardi, avril 9, 2024
Toxicity, Flow cytometry, Labs, Bone marrow, AML, Patient, Cytarabine, Acute myeloid leukemia, PLK1, AACR, BSA, De novo, Poster, Pharmaceutical industry

“We are very pleased to share more data regarding our clinical program and proprietary platform with the oncology community at AACR 2024.

Key Points: 
  • “We are very pleased to share more data regarding our clinical program and proprietary platform with the oncology community at AACR 2024.
  • Our clinical program will incorporate the co-development of a companion diagnostic test,” said Thomas Bock, M.D., Chief Executive Officer of Notable.
  • Notable Labs provided an updated plan for the design of an open label Phase 2 study, including a dose optimization plan aimed at reducing toxicity while maintaining efficacy and an overview of study objectives and endpoints.
  • These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Retrieved on: 
Lundi, avril 8, 2024
Ovarian cancer, Cetuximab, CRDF, RAS, Patient, Bev, PLK1, Abstract, AACR, Bevacizumab, Cancer, Phase, Data, SCLC, Pharmaceutical industry

In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.

Key Points: 
  • In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.
  • In addition, we are particularly encouraged by our RAS-mutated mCRC preclinical data highlighting onvansertib’s ability to inhibit activation of the hypoxia pathway via the regulation of HIF1α.
  • All the abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following the presentation, the posters will be posted to the “ Scientific Presentations ” section of the Cardiff Oncology website.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Mardi, mars 26, 2024
Ovarian cancer, Cyclin, IND, Therapy, Anemia, Research, University, Cell cycle, MD Anderson Cancer Center, PLK1, DDR, Investigational New Drug, Safety, Pharmacokinetics, Synthetic lethality, WEE1, U.S. FDA, Mutation, Acceleration, Part, HERG, ATR, KOL, Acquisition, Cancer, AACR, Research and development, Poster, FDA, Cyclin E, Toxicity, Aplastic anemia, Administration, Conference, APRE, PLK3, PLK2, Division, Data, Cardiotoxicity, Pharmaceutical industry

DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • “Aprea had a very productive 2023 with significant progress across our diversified pipeline of synthetic lethality-based cancer therapeutics.
  • An update from Part 1 of the trial was featured in a poster presentation at the AACR-NCI-EORTC International Conference in October 2023.
  • Select Financial Results for the Fourth Quarter ended December 31, 2023
    As of December 31, 2023, Aprea reported cash and cash equivalents of $21.6 million.
  • Research and Development (R&D) expenses were $2.0 million for the quarter ended December 31, 2023, compared to $0.5 million for the fourth quarter of 2022.

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mardi, mars 19, 2024
Research, Mutation, T-cell lymphoma, PD, ARID1A, Webcast, Patient, Lung, CDK, PLK1, Medicine, Clinical trial, CYCC, Cancer, Safety, Cyclacel, Lymphoma

BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
  • These include pharmacokinetic (PK), pharmacodynamic (PD), safety and activity data from the dose escalation part of the 065-101 Phase 1/2 study.
  • "We expect to report final Phase 1 results including details on patient genomic profiles at an upcoming medical conference.
  • ( Webcast link )
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Retrieved on: 
Mercredi, mars 6, 2024
Online, Carboplatin, CRDF, SAN, Cancer, Progression-free survival, PDX, Cetuximab, EGFR, Bev, Carcinoma, FOLFIRI, PLK1, AACR, Bevacizumab, RAS, Cisplatin, Ovarian cancer, Abstract, Paclitaxel, Patient, Clinical trial, Mutation, Publication, Vaccine

“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.

Key Points: 
  • “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
  • We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
  • The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

Retrieved on: 
Mardi, mars 5, 2024
Patient, AML, PLK1, AACR, Pharmaceutical industry

FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
  • “We expect to initiate the Phase 2 program for volasertib in patients with relapsed/refractory acute myeloid leukemia (r/r AML) utilizing our PPMP in Q2 2024.
  • As we advance preparations for the study, we are pleased to share more data with the oncology community at AACR 2024 regarding our PPMP platform, including preclinical studies related to volasertib and innovation related to clinical response prediction from cryopreserved patient samples,” said Thomas Bock, M.D., Chief Executive Officer of Notable Labs.
  • Poster #1: Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

Retrieved on: 
Mardi, mars 5, 2024
Patient, AML, PLK1, AACR, Pharmaceutical industry

FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
  • “We expect to initiate the Phase 2 program for volasertib in patients with relapsed/refractory acute myeloid leukemia (r/r AML) utilizing our PPMP in Q2 2024.
  • As we advance preparations for the study, we are pleased to share more data with the oncology community at AACR 2024 regarding our PPMP platform, including preclinical studies related to volasertib and innovation related to clinical response prediction from cryopreserved patient samples,” said Thomas Bock, M.D., Chief Executive Officer of Notable Labs.
  • Poster #1: Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Retrieved on: 
Jeudi, février 29, 2024
CRDF, SAN, Research, Investment, Cancer, Bev, FOLFIRI, PLK1, Bevacizumab, Standard of care, Clinical Cancer Research, Interim, Safety, Patient, SOC, Pharmaceutical industry

New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.

Key Points: 
  • New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.
  • Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • Full Year 2023 Financial Results:
    As of December 31, 2023, Cardiff Oncology had approximately $75 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024.